Akums Drugs &

Akums Drugs reported a strong Q4 FY26 with consolidated revenue of ₹1,158 croreCurrent reported value: ₹1,158 crore. No comparable prior figure is available in the source record. (+9.7Current 9.7 crore vs previous available quarter 14.8 crore.% YoY) and adjusted EBITDA of ₹152 croreCurrent ₹152 crore vs previous available quarter ₹147 crore. (+61.6% YoY), driven by robust CDMO volume growth of over 25%Current 25%. Reported change: +25pp YoY. in H2. The CDMO segment posted revenue of ₹952 croreCurrent reported value: ₹952 crore. No comparable prior figure is available in the source record. (+13.4% YoY) with EBITDA margins expanding to 14.4%Current 14.4%. Reported change: +550bps YoY. on operating leverage and improved product mix. Domestic branded formulations grew modestly but margins improved, while trade generics turned EBITDA positive. API business remained a drag with losses of ₹12 crore in Q4. Management guided for continued double-digit CDMO volume growth in H1 FY27, with the Zambia contract (USD 25 million annually) expected to commence by Q2 FY27 and the European CDMO contract (€35 million annual run-rate) from FY28. Capex for FY27 is planned at ₹300 crore. Key risk: sustained API price weakness or further erosion could delay the turnaround in the API segment.